Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Long-Term Deferred Tax (2017 - 2023)

Aytu Biopharma (AYTU) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $23.3 million as the latest value for Q2 2019.

  • On a quarterly basis, Long-Term Deferred Tax rose 39.38% to $23.3 million in Q2 2019 year-over-year; TTM through Jun 2019 was $23.3 million, a 39.38% increase, with the full-year FY2019 number at $23.3 million, up 39.38% from a year prior.
  • Long-Term Deferred Tax was $23.3 million for Q2 2019 at Aytu Biopharma, up from $16.7 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $23.3 million in Q2 2019 to a low of $158000.0 in Q2 2015.
  • A 4-year average of $14.9 million and a median of $18.0 million in 2017 define the central range for Long-Term Deferred Tax.
  • Peak YoY movement for Long-Term Deferred Tax: fell 13.69% in 2018, then soared 39.38% in 2019.
  • Aytu Biopharma's Long-Term Deferred Tax stood at $158000.0 in 2015, then soared by 12158.86% to $19.4 million in 2017, then dropped by 13.69% to $16.7 million in 2018, then skyrocketed by 39.38% to $23.3 million in 2019.
  • Per Business Quant, the three most recent readings for AYTU's Long-Term Deferred Tax are $23.3 million (Q2 2019), $16.7 million (Q2 2018), and $19.4 million (Q2 2017).